SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Northfield Lab(NFLD)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: wlheatmoon who wrote (37)10/17/1997 12:58:00 PM
From: borb   of 148
 
Here is another good one:

RESEARCH ALERT - Northfield Labs started

CHICAGO, Oct 17 (Reuters) - Vector Securities International said on Friday it started coverage
of Northfield Laboratories Inc as attractive.

Analyst Peter Drake said he initiated coverage with a target price of $19 per share, based
on ''exciting potential'' of the company's Phase III PolyHeme blood substitute.
He cited two risk factors behind the attractive rating. He noted that the company needs a
commercialization partner for the product, and said without a partner it will not cover the
expense of building a PolyHeme manufacturing plant.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News